243719 PROMIS measures in substance use treatment patients and general population

Tuesday, November 1, 2011

Katharina Wiest, PhD , Research Department, CODA, Inc, Portland, OR
Jason B. Colditz, BS , Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA
Dennis McCarty, PhD , Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR
Timothy T. Hartnett, MSW, MHA , Executive Director, CODA, Inc, Portland, OR
T. Ron Jackson, MSW , Administration, Evergreen Treatment Services, Seattle, WA
Paul A. Pilkonis, PhD , Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA
The National Institutes of Health's Patient-Reported Outcomes Measurement Information System (PROMIS) reliably and validly measures health outcomes using computer-assisted testing and scales developed with item response theory. PROMIS scales were used to explore drug practices and beliefs, and pain and emotional measures among participants (n = 404) within the first 30 days of beginning methadone (n = 168) and outpatient (n = 236) substance use disorder (SUD) treatment in 2010. The comparison group (n =1000) completed study measures through the YouGov Polimetrix internet panel. Study participation required respondents to report at least one alcoholic drink in the 30 days prior to completing the survey. SUD participants were more likely to be male, younger, less educated, current and/or former smoker than the comparison population. Polysubstance use was common for both men (43%) and women (48%) within both SUD samples. Abuse of alcohol and opiates were comparable between men and women in SUD treatment. SUD participants, regardless of diagnosis, were more likely to drink while taking prescription medications, mix alcohol and drugs to get high, and drink because of physical pain, anxiety, depression, anger, loneliness, sadness, nervousness as well as other emotional markers. SUD opioid respondents were more likely to report significant pain interference scores relative to the comparison group or other SUD. Prior analyses showed elevated scores of pain interference, anxiety, depression, and fatigue in SUD participants. Incorporating treatment practices directed to polysubstance use patients with pain interference and related distress may enhance treatment efficacy.

Learning Areas:
Public health or related research

Learning Objectives:
1. List three differences in beliefs about drugs between patients in substance use disorder treatment and the general population. 2. Articulate some of the barriers to receiving treatment for substance use disorders. 3. Develop a treatment plan for an opiate dependent woman who a concurrent alcohol dependence.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am director of research for a substance use disorder treatment provider and conduct related research.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.